enzastaurin has been researched along with vatalanib in 3 studies
| Studies (enzastaurin) | Trials (enzastaurin) | Recent Studies (post-2010) (enzastaurin) | Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) |
|---|---|---|---|---|---|
| 188 | 52 | 99 | 276 | 42 | 98 |
| Protein | Taxonomy | enzastaurin (IC50) | vatalanib (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.4577 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.2013 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.73 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.1192 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.1475 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.378 | |
| Vascular endothelial growth factor receptor 2 | Danio rerio (zebrafish) | 0.49 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Anderson, KC; Podar, K | 1 |
1 review(s) available for enzastaurin and vatalanib
| Article | Year |
|---|---|
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
2 other study(ies) available for enzastaurin and vatalanib
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |